U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H42N8O3
Molecular Weight 562.7063
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PINOMETOSTAT, TRANS-

SMILES

CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3N)[C@H]4C[C@H](CCC5=NC6=C(N5)C=CC(=C6)C(C)(C)C)C4

InChI

InChIKey=LXFOLMYKSYSZQS-YKPYGOBTSA-N
InChI=1S/C30H42N8O3/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33)/t17-,19-,22-,25-,26-,29-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://encrypted.google.com/patents/WO2012075381A1

Pinometostat, trans- (9H-Purin-6-amine, 9-[5-deoxy-5-[[trans-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methyl ethyl)amino]-β-D-ribofuranosyl]-) is an isomer of Pinometostat, a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Pinometostat, trans-specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.73 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
2013-08-08
The pathogenesis of mixed-lineage leukemia.
2012
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
2011-07-12
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
Human leukemia cell line EOL-1 were used for activity evaluation. Exponentially growing EOL-1 cells were plated in 96-well plates at a density of 3×10^4 viable cells/well. Each treatment was seeded in triplicate with a final well volume of 150 μLs. Cells were incubated with increasing concentrations of DOT1L inhibitor up to 50 μΜ. Viable cell number was determined every 3 - 4 days for 11 days using the Guava Viacount assay (Millipore # 4000-0040) and analyzed on a Guava EasyCyte Plus instrument according to the manufacturer's protocol.
Name Type Language
PINOMETOSTAT, TRANS-
Common Name English
9H-PURIN-6-AMINE, 9-(5-DEOXY-5-((TRANS-3-(2-(6-(1,1-DIMETHYLETHYL)-1H-BENZIMIDAZOL-2-YL)ETHYL)CYCLOBUTYL)(1-METHYLETHYL)AMINO)-.BETA.-D-RIBOFURANOSYL)-
Preferred Name English
Code System Code Type Description
PUBCHEM
57345410
Created by admin on Mon Mar 31 21:58:01 GMT 2025 , Edited by admin on Mon Mar 31 21:58:01 GMT 2025
PRIMARY
CAS
1380288-88-9
Created by admin on Mon Mar 31 21:58:01 GMT 2025 , Edited by admin on Mon Mar 31 21:58:01 GMT 2025
PRIMARY
FDA UNII
F66X4M38G5
Created by admin on Mon Mar 31 21:58:01 GMT 2025 , Edited by admin on Mon Mar 31 21:58:01 GMT 2025
PRIMARY